Renal & Urinary

Asymptomatic bacteriuria: when to treat

Clinical Overview and When to Suspect Asymptomatic Bacteriuria

— Women: ≥10⁵ CFU/mL of the same organism in two consecutive voided specimens

— Men: ≥10⁵ CFU/mL in a single voided specimen

— Either sex: ≥10² CFU/mL in a single catheterized specimen

— Healthy premenopausal women: 1–5%

— Pregnant women: 2–10%

— Postmenopausal women 50–70 yrs: ~5–10%

— Elderly community-dwelling women: up to 20%

— Elderly in long-term care: 25–50% (women), 15–40% (men)

— Long-term indwelling catheter: essentially 100%

— Diabetes (women): 10–15%

Board pearl: Only two populations clearly benefit from screening and treating ASB: (1) pregnant women and (2) patients about to undergo a urologic procedure with anticipated mucosal trauma/bleeding (e.g., TURP, TURBT, ureteroscopy with stone manipulation). Memorize these; every other scenario on the exam is a distractor designed to trap reflexive antibiotic prescribing.

Definition: Asymptomatic bacteriuria (ASB) = isolation of bacteria in significant quantity from a properly collected urine specimen in a patient without signs or symptoms referable to the urinary tract.

Pyuria alone does NOT define UTI and does not convert ASB into symptomatic infection — its presence in ASB is common and should not trigger antibiotics.

Epidemiology — prevalence climbs with age and comorbidity:

When to suspect ASB on the exam stem: an incidentally positive urinalysis or urine culture obtained for screening, preoperative clearance, fatigue, falls, mild confusion in the elderly, foul-smelling/cloudy urine, or routine catheter change — without dysuria, frequency, urgency, suprapubic pain, flank pain, fever, or new urinary symptoms.

The core Step 3 teaching: ASB is mostly a do-not-treat diagnosis. Treating it does not reduce symptomatic UTIs, mortality, or incontinence, but it does drive C. difficile, resistance, adverse drug effects, and Medicare quality-metric failures.

Presentation Patterns and Key History

— "Routine annual exam" UA in an asymptomatic 72-year-old woman → leukocytes and nitrites positive

— Preoperative clearance UA before knee arthroplasty

— Nursing home resident with "change in mental status" and a positive UA

— Diabetic outpatient with cloudy, malodorous urine but no dysuria

— Indwelling Foley patient during routine catheter change

— Pregnant patient at first prenatal visit

— Dysuria, urinary frequency, urgency, hesitancy

— Suprapubic pain or tenderness

— Flank pain, CVA tenderness, fever, chills, rigors

— Hematuria (new), new incontinence, acute retention

— Nausea, vomiting, malaise specifically attributed to GU source

Key distinction: CA-ASB vs CA-UTI — both have bacteriuria, but CA-UTI requires new systemic or localized symptoms (fever, rigors, altered mental status with no other cause identified, flank pain, acute hematuria, pelvic discomfort). Without those, it remains CA-ASB and should not be treated.

Step 3 management: When the stem hands you a positive UA in an asymptomatic patient, your first move is almost always "no antibiotics, no repeat culture" unless the patient is pregnant or scheduled for an invasive urologic procedure. Anchor on this before considering any other answer.

Classic vignette setup: urinalysis or urine culture ordered for the wrong reason, then a positive result forces a management decision.

Key history to actively elicit (and document as absent):

Mental status changes — the trap: In frail elderly or LTC residents, "altered mental status" alone is not a urinary symptom. Current IDSA (2019) guidance: pursue alternative causes (dehydration, medications, hypoxia, electrolytes, infection elsewhere) before attributing delirium to bacteriuria.

Catheter-associated ASB (CA-ASB): by definition asymptomatic — odor, cloudiness, and sediment in the bag are not indications to treat.

Cloudy/foul urine: reflects concentration, crystalluria, or colonization — not infection. Hydration, not antibiotics.

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Afebrile (T <38.0°C). Any fever attributable to GU source pushes the diagnosis toward cystitis or pyelonephritis.

— Normotensive, no tachycardia, no tachypnea — absence of SIRS/qSOFA criteria

— In elderly or septic-appearing patients, recheck temperature rectally; hypothermia can mask urosepsis

— No suprapubic tenderness

— No costovertebral angle (CVA) tenderness on percussion

— No palpable bladder (rule out retention, which can mimic or precipitate symptomatic UTI)

— In men: prostate exam if any consideration of prostatitis (boggy, tender prostate → not ASB)

Board pearl: A "septic-appearing" elderly patient with a positive UA and no other symptoms is the highest-stakes ASB trap on Step 3. Order a broad workup (CXR, blood cultures, lactate, abdominal exam, skin exam, lines/devices) before declaring urosepsis. Many of these patients have pneumonia, C. difficile, or cholangitis with incidental bacteriuria.

CCS pearl: On a CCS case with an ambiguous febrile elder, order blood cultures × 2, CXR, CBC, BMP, lactate, urine culture before committing to "treat UTI" — and reassess at the next clock advance. Premature antibiotic narrowing to a urinary diagnosis loses points.

The exam in ASB is, by definition, unremarkable from a urinary standpoint. The clinical value of the exam is to rule out symptomatic infection or an alternative source for any nonspecific findings.

Vital signs:

Abdominal/GU exam:

Pelvic exam in women: consider when discharge, atrophy, or vaginitis could explain the UA findings. Vaginal atrophy and contamination are major reasons UAs look "positive" in postmenopausal women.

Mental status: baseline cognition documented; if altered, document alternative explanations sought (medication review, hydration, oxygenation, glucose, alternative infection sites — chest, skin, abdomen).

Catheterized patients: inspect the catheter and meatus for purulence, inspect drainage tubing, palpate the bladder for retention/obstruction, check for suprapubic catheter site infection — local findings change the diagnosis to CA-UTI or catheter-site cellulitis.

Diagnostic Workup — Initial Labs / Imaging / ECG / Biomarkers

— Indications for UA: urinary symptoms, pregnancy screening (first prenatal visit), preoperative urologic procedure, evaluation of unexplained AKI/hematuria

— Not indicated: routine annual exam, preoperative clearance for non-urologic surgery, "change in mental status" without other features, evaluation of malodorous urine alone

— Leukocyte esterase: marker of pyuria; common in ASB and not diagnostic of infection

— Nitrites: indicate nitrate-reducing organisms (E. coli, Klebsiella, Proteus); enterococcus, S. saprophyticus, pseudomonas are nitrite-negative

— Pyuria (WBC >10/hpf): present in most ASB and nearly all CA-ASB — does not justify treatment

— Squamous epithelial cells >5/hpf suggest contamination → repeat with clean catch or catheterized sample if truly needed

— Gold standard for quantifying bacteriuria

— Order only when result would change management — i.e., pregnancy, pre-urologic procedure, or symptomatic infection

— Diagnostic thresholds (see Chunk 1): two consecutive ≥10⁵ in women, one ≥10⁵ in men, ≥10² in catheterized

Key distinction: A positive dipstick does not equal infection. Treatment decisions hinge on symptoms plus a properly interpreted culture, not the dipstick.

Step 3 management: The highest-yield diagnostic intervention for suspected ASB is often not ordering a urine culture in the first place — "diagnostic stewardship" is now a quality metric and a frequent correct answer.

Urinalysis (UA): the most common entry point, often inappropriately ordered.

UA interpretation:

Urine culture:

Common organisms: E. coli most common across groups; in LTC and catheterized patients, expect more Klebsiella, Proteus, Enterococcus, Pseudomonas, polymicrobial growth.

Biomarkers: CRP, procalcitonin, WBC — not validated for distinguishing ASB from UTI; do not treat based on these alone.

Imaging/ECG: not indicated for ASB itself. Renal ultrasound only if obstruction, stones, or pyelonephritis suspected.

Diagnostic Workup — Advanced or Confirmatory Studies

— Collect from sampling port after disinfection, not from the drainage bag

— If a chronic catheter has been in place >2 weeks and infection truly suspected, replace the catheter and obtain the culture from the newly placed device — colonized biofilm cultures are misleading

— Recurrent culture-positive episodes in men: consider prostatitis, BPH with retention, urolithiasis — obtain post-void residual, consider urology referral

— Persistent Proteus bacteriuria: consider struvite (staghorn) stones — order renal US or non-contrast CT

— Unexplained candiduria: usually colonization; treat only if symptomatic, neutropenic, or pre-urologic procedure

— Group B Streptococcus (GBS) in urine during pregnancy: any GBS bacteriuria (even <10⁵) → treat the bacteriuria and administer intrapartum antibiotic prophylaxis (woman is heavily colonized)

— Renal/bladder ultrasound: for retention, hydronephrosis, stones in recurrent disease

— CT abdomen/pelvis without contrast: stones, emphysematous pyelonephritis if symptoms develop

— Cystoscopy: for persistent hematuria or suspected anatomic abnormality

Board pearl: Proteus mirabilis + persistent ASB + alkaline urine = think struvite stone and image the kidneys; treating the bacteriuria without addressing the nidus guarantees recurrence.

Key distinction: GBS bacteriuria in pregnancy is the one organism-specific exception that always triggers both treatment and later intrapartum prophylaxis — high-yield Step 3 trap.

Confirmatory testing in women: ASB in nonpregnant women requires two consecutive positive cultures with the same organism at ≥10⁵ CFU/mL. A single positive culture in an asymptomatic woman may reflect contamination; if treatment is being considered (rare — pregnancy, pre-procedure), confirm before committing.

Men: a single voided ≥10⁵ CFU/mL is sufficient; contamination is less likely anatomically.

Catheterized specimens:

Special situations requiring extended workup:

Imaging — when ASB workup tips into more:

Pregnancy-specific: screen with urine culture at 12–16 weeks (first prenatal visit); dipstick alone is insufficient. Re-screen if symptoms develop or after treatment to confirm cure.

Risk Stratification or First-Line Management Logic

— Treat ASB:

1. Pregnancy (any trimester, any organism, any CFU count for GBS)

2. Before urologic procedures with anticipated mucosal trauma/bleeding (TURP, TURBT, ureteroscopy with stone manipulation, prostate biopsy)

— Do NOT treat ASB:

— Does not reduce symptomatic UTI, sepsis, mortality, or incontinence

— Increases antimicrobial resistance, C. difficile, drug adverse events, and cost

— In elderly women, may actually increase subsequent symptomatic UTI by disrupting protective flora

Step 3 management: When a stem asks "next best step" for ASB in any population not on the pregnancy / pre-urologic procedure list, the correct answer is reassurance and no antibiotic, no repeat culture. Choosing nitrofurantoin or TMP-SMX in these stems is the wrong answer 95% of the time.

Board pearl: The 2019 IDSA guideline explicitly removed "preoperative non-urologic surgery" — including joint replacement — from the treat list. This is a hot Step 3 update.

The decision tree — memorize cold:

Healthy nonpregnant women (premenopausal or postmenopausal)

Diabetic patients (men or women)

Elderly community-dwelling adults

Elderly institutionalized/LTC residents

Patients with spinal cord injury

Patients with short-term or long-term indwelling catheters (including CA-ASB)

Renal transplant recipients >1 month post-transplant (recent 2019 IDSA update — older teaching is outdated)

Patients undergoing non-urologic surgery (including arthroplasty — major change from historical practice)

Why the restraint? Multiple RCTs and meta-analyses show that treating ASB:

Renal transplant nuance: Treat ASB only in the first month post-transplant when surgical anastomoses are healing and immunosuppression is at induction-level intensity. Beyond 1 month, observe.

Neutropenic patients: Evidence is limited; IDSA does not routinely recommend screening or treating ASB. Treat if symptomatic or if institutional protocols dictate during deep neutropenia.

Pharmacotherapy — First-Line Drug Regimen

Pregnancy (treat for 4–7 days, then test-of-cure culture 1–2 weeks later):

— Nitrofurantoin 100 mg PO BID × 5–7 days — avoid at term (≥36 weeks) due to neonatal hemolysis risk; avoid in G6PD deficiency

— Cephalexin 500 mg PO QID × 5–7 days — safe across all trimesters; reasonable first choice

— Amoxicillin-clavulanate 500/125 mg PO BID × 5–7 days — if susceptibility supports

— Fosfomycin 3 g PO single dose — convenient; effective for E. coli

— TMP-SMX: avoid in 1st trimester (folate antagonism, neural tube defects) and near term (kernicterus, hyperbilirubinemia); acceptable mid-pregnancy with folate supplementation if no alternatives

— Fluoroquinolones: avoid in pregnancy (cartilage concerns)

— GBS in urine: treat the bacteriuria with a β-lactam (penicillin, ampicillin, or cephalexin) and give intrapartum penicillin/ampicillin prophylaxis during labor

Pre-urologic procedure prophylaxis:

— Obtain urine culture before the procedure and tailor to susceptibilities

— Administer a short course timed to start shortly before the procedure and continue no longer than 24 hours postoperatively

— Reasonable agents: TMP-SMX, cephalosporins, fluoroquinolone, or aminoglycoside — culture-driven

— Treating CA-ASB at catheter change (not indicated)

— Empiric fluoroquinolone for "complicated UTI" when the patient has no symptoms

— Prolonged suppressive therapy for recurrent ASB

Key distinction: Fosfomycin for cystitis is a single dose; for pyelonephritis or complicated infections it should not be used as monotherapy. In pregnant ASB it is a reasonable single-dose option.

Board pearl: In a pregnant patient with ASB at term, choose cephalexin over nitrofurantoin and TMP-SMX — both alternatives have late-pregnancy fetal risks.

When treatment is indicated, choose by patient and culture:

Duration discipline: prolonged courses for ASB even when indicated are inappropriate; aim for the shortest evidence-based course.

Renal transplant (<1 month post-op): culture-directed, typically 5–7 days, narrow spectrum preferred.

Avoid these reflexes:

Procedures / Revascularization / Invasive Management (or expanded pharmacology if non-procedural)

— Remove unnecessary catheters. The single most effective intervention to reduce CA-ASB → CA-UTI progression is discontinuation of indwelling catheters as soon as clinically possible.

— Acceptable Foley indications: acute retention, accurate I/O in critically ill, prolonged immobilization, perioperative for select surgeries, end-of-life comfort, stage III–IV pressure ulcer with incontinence

— Convert to intermittent catheterization or external (condom) catheter when feasible — both reduce bacteriuria and symptomatic UTI compared to chronic indwelling

— Catheter exchange before sampling if culture truly needed in a chronically catheterized patient with new symptoms

— Obtain urine culture days in advance

— If positive ASB → targeted antibiotic starting just before procedure, ≤24 hr post-procedure

— If culture cannot be obtained, use a broad-spectrum agent per local antibiogram

— Methenamine hippurate has evidence for prevention of recurrent symptomatic UTI in women, but is not indicated for treatment of ASB

— Topical vaginal estrogen in postmenopausal women reduces recurrent symptomatic UTI; not an ASB treatment

— Cranberry products: weak evidence; not a treatment

— Struvite stones with persistent Proteus bacteriuria → urology referral for stone removal (PCNL) — antibiotics alone will not clear the source

— BPH with chronic retention → consider TURP after appropriate workup

— Order sets that block reflex urine cultures in asymptomatic patients

— Pharmacist-driven de-escalation

Step 3 management: For a hospitalized patient with a Foley and a "positive UA," the highest-value order is often "discontinue Foley" rather than "start ceftriaxone."

CCS pearl: On CCS, advancing the clock after removing an unnecessary catheter and not treating CA-ASB earns stewardship credit; reflexive empiric antibiotics lose points.

Catheter management — the most actionable "procedure" in ASB:

Pre-urologic procedure workflow:

Procedures NOT requiring ASB treatment: simple cystoscopy without biopsy, urodynamic studies, routine catheter exchange.

Suppressive therapy / cranberry / methenamine:

Surgical correction of underlying anatomy:

Antimicrobial stewardship intervention:

Special Populations — Elderly and Renal/Hepatic Impairment

— Up to 50% of LTC women and 40% of LTC men have ASB at any given time

— Do not screen with routine UAs

— Do not treat positive cultures unless localizing urinary symptoms develop

— "Change in mental status" alone is not a symptom — pursue alternatives first

— Cloudy/foul urine, sediment, and incontinence are not indications

— High C. difficile risk (advanced age, multiple comorbidities, polypharmacy)

— Drug interactions: fluoroquinolones with warfarin, QT prolongation, tendinopathy, aortic dissection risk; nitrofurantoin pulmonary fibrosis with prolonged use

— Selection of MDR organisms in congregate settings

— Nitrofurantoin: avoid if CrCl <30 mL/min (and use caution at 30–60); inadequate urinary concentration and increased toxicity

— TMP-SMX: dose-reduce at CrCl <30; watch for hyperkalemia, AKI from creatinine secretion blockade

— Fluoroquinolones: renal dose adjustment; QT, tendon, aortic, glycemic, and CNS adverse effects amplified in elderly

— β-lactams (cephalexin, amoxicillin-clavulanate): renal dose adjustment; generally safest in elderly

— Fosfomycin: caution if CrCl <30; reduced urinary concentrations

Board pearl: Nitrofurantoin in CrCl <30 is a Beers Criteria avoidance — both for inefficacy and toxicity. Choose a β-lactam in the elderly with renal impairment when treatment is genuinely needed.

Step 3 management: A nursing home resident with a positive UA and "increased confusion": evaluate hydration, medications, oxygenation, and other infection sites; observe urine, do not treat unless localizing symptoms or hemodynamic instability emerge.

Elderly community-dwelling and LTC residents — the #1 trap population:

Why treating elderly ASB harms:

Renal impairment dosing when treatment IS indicated:

Hepatic impairment: most urinary antibiotics are renally cleared; nitrofurantoin can rarely cause hepatotoxicity (acute and chronic) — avoid in known hepatic disease.

Fall risk and polypharmacy: every added antibiotic in the elderly raises fall risk via dizziness, hypoglycemia (fluoroquinolones), C. difficile dehydration.

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Untreated ASB in pregnancy → 20–30% risk of pyelonephritis, plus preterm birth, low birth weight, and perinatal mortality

— USPSTF Grade A recommendation: screen all pregnant women with urine culture at 12–16 weeks gestation (or first prenatal visit if later)

— Treat per Chunk 7; perform test-of-cure culture 1–2 weeks after completion

— Recurrent or persistent bacteriuria → consider suppressive prophylaxis for remainder of pregnancy (e.g., nightly nitrofurantoin or cephalexin, stopped before term for nitrofurantoin)

— GBS in urine at any count → treat the episode and intrapartum penicillin prophylaxis during labor regardless of late rectovaginal screen

— ASB in children is uncommon; routine screening is not recommended

— Treatment of pediatric ASB does not reduce renal scarring or recurrence and may select resistance

— Exception: pediatric urologic procedures or significant urinary tract anomalies under specialist guidance

— High prevalence of bacteriuria, especially with intermittent or indwelling catheterization

— Do not screen, do not treat asymptomatic patients

— Treat only when symptomatic (fever, autonomic dysreflexia attributable to GU source, increased spasticity with localizing findings)

— Treat ASB only in the first month post-transplant

— Beyond 1 month: routine screening and treatment not recommended (RCT evidence)

— Higher ASB prevalence but no benefit to treatment

— Manage glycemic control instead

Key distinction: Pregnancy ASB = always treat with test of cure. Pediatric, diabetic, SCI, and post–1-month transplant ASB = do not treat. These pairings are recurrent Step 3 question targets.

Board pearl: First prenatal visit checklist must include a urine culture — dipstick or UA alone fails the standard of care.

Pregnancy — the cornerstone indication to treat:

Pediatrics:

Spinal cord injury / neurogenic bladder:

Renal transplant:

Diabetes mellitus:

Solid organ transplant (non-renal), HIV, neutropenia: generally do not screen/treat ASB unless symptomatic or per institutional protocol.

Complications and Adverse Outcomes

— Healthy nonpregnant adults, diabetics, elderly: no increase in mortality, pyelonephritis rates, or renal decline from observation

— Catheterized patients: most CA-ASB resolves with catheter removal; symptomatic CA-UTI rate per CA-ASB day is low

— Pregnancy: 20–30% progress to pyelonephritis, with associated preterm labor, low birth weight, sepsis, and perinatal mortality

— Pre-urologic procedure: untreated bacteriuria during mucosal trauma → bacteremia and urosepsis in up to 6–10% of cases

— Early post–renal transplant: allograft pyelonephritis, possible graft dysfunction

— Clostridioides difficile infection: fluoroquinolones, cephalosporins, and clindamycin are highest risk; elderly and hospitalized most vulnerable

— Antimicrobial resistance: emergence of ESBL, fluoroquinolone-resistant E. coli, VRE

— Adverse drug reactions:

— Disrupted protective vaginal/gut flora → paradoxically increased subsequent symptomatic UTI in elderly women

— Drug-drug interactions: warfarin (TMP-SMX, fluoroquinolones), sulfonylureas (hypoglycemia), QT-prolonging meds

Board pearl: A vignette with an elderly patient given a fluoroquinolone for "UTI" (really ASB) who returns with C. difficile colitis or a ruptured Achilles tendon is a classic Step 3 cause-and-effect stem — the teaching point is the initial inappropriate treatment.

Step 3 management: Document the indication and absence of symptoms at the time of antibiotic order; this protects both the patient and the prescribing decision in chart audits.

Complications of UNTREATED ASB — limited in most populations:

Complications of UNTREATED ASB in high-risk groups:

Complications of INAPPROPRIATELY TREATING ASB — what Step 3 tests:

Fluoroquinolones: tendinopathy/rupture, aortic aneurysm/dissection, QT prolongation, hypoglycemia, peripheral neuropathy, CNS effects, dysglycemia

TMP-SMX: hyperkalemia, AKI, SJS/TEN, hemolysis in G6PD, bone marrow suppression, hyponatremia

Nitrofurantoin: acute pneumonitis, chronic pulmonary fibrosis (long-term), hepatotoxicity, peripheral neuropathy in renal impairment

β-lactams: anaphylaxis, rash, interstitial nephritis

System-level complications: wasted hospital days, additional cultures, blood draws, IV access, contributing to hospital-acquired complications.

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Fever, rigors, hypotension, tachycardia, tachypnea

— Flank pain, CVA tenderness, suprapubic pain

— New gross hematuria, acute urinary retention

— Sepsis criteria (qSOFA ≥2, lactate >2, organ dysfunction)

— In SCI: autonomic dysreflexia attributable to urinary source, increased spasticity

— In pregnancy: any urinary symptoms, fever, contractions

— Symptomatic UTI with sepsis → admit; broad empiric antibiotics (e.g., ceftriaxone or piperacillin-tazobactam depending on severity and risk for resistant organisms), IV fluids, blood and urine cultures, source control

— Pregnancy + pyelonephritis → admit (historically all such patients; selected reliable patients with mild disease may be managed outpatient after observation)

— Obstructive uropathy with infection → emergent urology consult for decompression (stent or percutaneous nephrostomy) — antibiotics alone fatal

— Urology: recurrent ASB with structural concern, struvite stones, persistent post-procedure bacteriuria, BPH with retention

— Infectious diseases: MDR organisms in pre-procedure ASB needing tailored prophylaxis; complex transplant cases

— Maternal-fetal medicine: recurrent pyelonephritis in pregnancy, persistent bacteriuria despite therapy

— Antimicrobial stewardship: when audit identifies repeated inappropriate ASB treatment

CCS pearl: On a CCS case where you correctly chose to not treat ASB but the patient later develops fever and flank pain at the next clock advance, immediately order blood cultures, urine culture (now indicated), CBC, BMP, lactate, and start empiric IV antibiotics — the case has converted to symptomatic pyelonephritis.

Key distinction: Decompression of an obstructed infected kidney is a surgical emergency; antibiotics without source control will not save the patient.

ASB itself does not warrant escalation. Escalation triggers indicate that the diagnosis is no longer ASB.

Re-evaluate the diagnosis if any of these emerge:

Inpatient triage:

Consultations:

Disposition for incidental ASB in outpatient clinic: reassurance, education on when to seek care (new dysuria, fever, flank pain), no follow-up culture needed in nonpregnant patients.

Key Differentials — Same-Category Causes (Other Urinary/Infectious Mimics)

— Dysuria, frequency, urgency, suprapubic discomfort, no fever, no flank pain

— Treat empirically; nitrofurantoin 5 days, TMP-SMX 3 days, or fosfomycin single dose

— Distinguishing feature from ASB: symptoms

— Fever, flank pain, CVA tenderness, nausea/vomiting, often with lower tract symptoms

— Pyuria, bacteriuria, often bacteremia

— Outpatient fluoroquinolone (if local resistance <10%) or inpatient ceftriaxone; never just observe

— Structural/functional abnormality, male sex, pregnancy, catheter, immunocompromise, recent instrumentation

— Longer therapy, broader empiric coverage, imaging if no improvement

— Bacteriuria plus systemic or localizing symptoms with no other identified source

— Remove or exchange catheter, culture-directed therapy

— Men with dysuria, perineal/pelvic pain, fever, boggy tender prostate (do not vigorously massage in acute)

— Acute: fluoroquinolone or TMP-SMX 2–4 weeks (acute); chronic: 4–6 weeks

— Sexually active patient with dysuria, discharge; UA may show pyuria with sterile culture

— Test for gonorrhea/chlamydia; treat with ceftriaxone + doxycycline

— Postmenopausal women with dysuria, irritation, contaminated UAs

— Topical vaginal estrogen; not antibiotics

— Chronic suprapubic pain, frequency, urgency, negative cultures

— Lifestyle, pelvic floor PT, amitriptyline, hydroxyzine, pentosan polysulfate

Key distinction: Pyuria with negative culture in a sexually active patient → think urethritis (chlamydia/gonorrhea), not ASB. Get NAAT.

Board pearl: "Dysuria" in a postmenopausal woman with a marginally positive UA is more likely atrophic vaginitis than infection — exam matters more than the dipstick.

Acute uncomplicated cystitis:

Acute pyelonephritis:

Complicated UTI:

Catheter-associated UTI (CA-UTI):

Prostatitis (acute and chronic bacterial):

Urethritis (STI):

Vaginitis / atrophic vaginitis:

Interstitial cystitis / bladder pain syndrome:

Key Differentials — Other-Category Causes (Non-Urinary Mimics)

— Real causes: dehydration, hypoxia, hyponatremia, hypercalcemia, hypoglycemia, medication adverse effects (anticholinergics, opioids, benzodiazepines), pneumonia, occult MI, stroke, C. difficile, fecal impaction, urinary retention

— Workup before urinary attribution: vitals trend, med review, CBC, BMP, glucose, calcium, CXR, neuro exam, bladder scan, stool studies if indicated

— Pneumonia, intra-abdominal (cholangitis, diverticulitis, appendicitis), skin/soft tissue, line-associated bacteremia, endocarditis

— Always perform a head-to-toe source search before anchoring on "urosepsis"

— Glomerulonephritis: hematuria, RBC casts, proteinuria, hypertension

— Nephrolithiasis: flank pain, hematuria, possibly pyuria without true infection

— Renal cell carcinoma: painless hematuria

— Squamous cells, mixed flora, lactobacilli

— Repeat with proper clean catch or catheterized sample only if clinically necessary

— Chemotherapy (cyclophosphamide → hemorrhagic cystitis)

— Ketamine cystitis

— Pelvic radiation cystitis

— Dehydration, asparagus, certain medications (sulfonamides, B vitamins), phosphate crystals

— Hydration and reassurance; not antibiotics

Board pearl: In a 78-year-old LTC resident with new "altered mental status" and a positive UA, the most commonly missed diagnoses are medication adverse effect, dehydration, and pneumonia — not UTI. Resist anchoring.

Step 3 management: Order a focused workup (CXR, BMP, med reconciliation, bladder scan) before initiating antibiotics for "urinary delirium" — premature antibiotic anchoring is both a clinical and exam pitfall.

Delirium in elderly attributed to "UTI":

Sepsis from non-urinary sources with incidental bacteriuria:

Renal pathology presenting with abnormal UA but no infection:

Vaginal contamination of UA:

Medication-induced urinary symptoms:

Foul-smelling/cloudy urine without infection:

Secondary Prevention / Discharge Medications / Long-Term Plan

— Patient education is the primary "discharge plan":

— Avoid follow-up urine cultures in nonpregnant adults — they only invite further unnecessary treatment

— Test-of-cure culture 1–2 weeks post-therapy

— Periodic surveillance cultures each trimester or per local protocol if first episode; many institutions repeat culture monthly through pregnancy after a positive screen

— Consider suppressive prophylaxis (nightly low-dose nitrofurantoin until 36 weeks, or cephalexin) for recurrent bacteriuria or pyelonephritis episodes during pregnancy

— Ensure intrapartum GBS prophylaxis documented if any GBS bacteriuria during pregnancy

— Behavioral: hydration, post-coital voiding, avoid spermicide

— Topical vaginal estrogen in postmenopausal women — reduces recurrence

— Methenamine hippurate — emerging evidence for prevention

— Cranberry products — modest, inconsistent evidence

— Antibiotic prophylaxis (continuous low-dose or post-coital) for highly recurrent symptomatic disease — never for ASB

— Discharge plan focuses on earliest possible removal, intermittent catheterization where feasible, perineal hygiene, closed drainage system, no routine antibiotic prophylaxis

— Document the indication for any continued catheterization at each encounter

— Note "asymptomatic bacteriuria, antibiotics not indicated" in the chart to prevent downstream re-treatment

Step 3 management: The discharge order set for incidentally identified ASB is essentially "no antibiotic, patient counseling, return precautions, no scheduled repeat UA/culture" — choosing this minimalist plan is usually the right answer.

Board pearl: Topical vaginal estrogen prevents symptomatic recurrent UTI in postmenopausal women — it is not a treatment for ASB.

For patients with ASB (not treated):

Reassure that bacteria in urine without symptoms is common and not harmful

Explain that antibiotics can cause more harm than benefit

Provide clear "return precautions": new dysuria, fever, flank pain, gross hematuria, inability to urinate

For pregnant patients treated for ASB:

Patients with recurrent symptomatic UTIs (separate entity, but commonly confused with ASB):

Catheterized patients:

Stewardship documentation:

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— No specific follow-up required for the bacteriuria itself

— Address the underlying reason a UA was ordered — was it appropriate?

— Routine annual visit cadence; no extra labs

— Test of cure 1–2 weeks post-treatment (urine culture)

— Continued surveillance per local protocol; many follow with monthly cultures

— Monitor for symptomatic progression — fever, flank pain, contractions

— Coordinate GBS prophylaxis plan with labor and delivery team if applicable

— Confirm urine sterilization (or appropriate antibiotic coverage at induction)

— Postoperative monitoring for fever, hematuria, urosepsis

— Catheter removal as early as appropriate post-procedure

— Monitor allograft function (creatinine), drug levels (tacrolimus interactions with TMP-SMX, fluoroquinolones), and rejection markers

— Coordinate closely with transplant team

— Daily reassessment of catheter necessity (CAUTI bundle)

— Watch for symptomatic progression: fever, suprapubic pain, hematuria, autonomic dysreflexia in SCI

— Document indication for ongoing catheterization

— Explain bacteriuria vs UTI in plain language; patients often demand antibiotics for "infection on the lab"

— Emphasize that overuse of antibiotics increases future resistant infections, C. difficile, and side effects

— Provide written return precautions

— Family education in LTC and home settings — caregivers often pressure for antibiotics on cloudy urine

— ASB inappropriate treatment is a tracked stewardship metric in many systems

— Document the clinical reasoning for not treating

Step 3 management: A pregnant patient post-treatment for ASB needs a test-of-cure urine culture at 1–2 weeks — not a dipstick, not "wait and see."

Board pearl: Daily Foley necessity reassessment ("Is the catheter still needed?") is both a CAUTI prevention bundle element and a high-yield exam answer.

Nonpregnant adults with incidental ASB:

Pregnant women treated for ASB:

Pre-urologic procedure patients:

Renal transplant patients (first month):

Catheterized patients (CA-ASB):

Counseling pearls:

Health-system / quality measures:

Ethical, Legal, and Patient Safety Considerations

— Inappropriate ASB treatment is a leading contributor to outpatient and LTC antibiotic overuse

— Each unnecessary course increases individual and community risks: C. difficile, MDR organisms, allergic reactions, adverse drug events

— Stewardship programs are now CMS-required for hospitals and many long-term care settings

— Patient discharged from hospital with a positive UA reflexively put on a 7-day course of ciprofloxacin → develops C. difficile at home, readmits

— Prevent: at discharge, review every antibiotic for indication, document "ASB, not treating" in the discharge summary, communicate clearly to receiving clinician (LTC facility, PCP), reconcile medications

— When a patient or family pressures for antibiotics on cloudy urine, explain risks/benefits, document the conversation, offer return precautions

— In LTC residents with cognitive impairment, involve healthcare proxies in discussions about not treating ASB

— While ASB is not reportable, resistant organisms (e.g., CRE, ESBL Enterobacterales) often are — appropriate handling of cultures and notification of public health matters

— Hospital-acquired CAUTI rates are publicly reported and tied to reimbursement

— Chart the absence of symptoms explicitly when declining to treat ("no dysuria, frequency, urgency, suprapubic pain, fever, flank pain")

— Document family discussions

— Avoid the diagnostic code "UTI" for ASB — it propagates inaccurate problem lists and downstream re-treatment

— A previously labeled "recurrent UTI" patient may actually have recurrent ASB; review prior cultures, symptoms, and the original justifications

— Antibiotic overprescribing for ASB disproportionately affects elderly women in LTC and patients with disabilities (SCI, neurogenic bladder) — both groups subject to assumption-based treatment

Step 3 management: When the stem describes a patient leaving the hospital with an "incidental positive UA," the safest discharge plan is no antibiotics, clear return precautions, explicit communication to the PCP, and corrected problem list — minimizing transition-of-care antibiotic harm.

Antimicrobial stewardship as patient safety:

Transition-of-care risk — high-yield Step 3 scenario:

Informed consent and shared decision-making:

Mandatory reporting and public health:

Documentation and medicolegal safety:

Avoiding diagnostic momentum:

Equity considerations:

High-Yield Associations and Rapid-Fire Clinical Facts

— Safe: cephalexin, amoxicillin-clavulanate, fosfomycin

— Nitrofurantoin: avoid at term (≥36 weeks) and in G6PD

— TMP-SMX: avoid 1st trimester and near term

— Fluoroquinolones: avoid throughout pregnancy

Board pearl: Two-question Step 3 reflex — "Is she pregnant?" and "Is she going to the OR for a urology procedure?" If both no, do not treat.

Always treat ASB in: pregnancy; before urologic procedures with mucosal trauma/bleeding (TURP, TURBT, ureteroscopy, prostate biopsy).

Never routinely treat ASB in: healthy nonpregnant women, diabetics, elderly, LTC residents, SCI, indwelling catheters, post-arthroplasty/orthopedic surgery patients, post-transplant >1 month.

Renal transplant exception: treat ASB only in the first month post-transplant.

Pregnancy ASB workup: urine culture at 12–16 weeks (first prenatal visit), USPSTF Grade A.

Pregnancy ASB threshold: ≥10⁵ CFU/mL of a uropathogen; GBS in urine at any count → treat the bacteriuria and provide intrapartum prophylaxis.

Untreated pregnancy ASB: 20–30% develop pyelonephritis; associated with preterm birth and low birth weight.

Antibiotics by trimester:

Quantitative thresholds: ≥10⁵ CFU/mL voided (2× in women, 1× in men), ≥10² catheterized.

Pyuria alone: does not define UTI and does not warrant treating ASB.

CA-ASB ≠ CA-UTI: symptoms make the difference.

Best CA-UTI prevention: remove the catheter.

Persistent Proteus bacteriuria: struvite stones — image the kidneys.

GBS bacteriuria during pregnancy: intrapartum penicillin prophylaxis even if late rectovaginal screen is negative.

Nitrofurantoin contraindications: CrCl <30 mL/min, G6PD deficiency, term pregnancy.

Fluoroquinolone harms (especially elderly): tendinopathy/rupture, aortic dissection, QT prolongation, hypoglycemia, peripheral neuropathy, CNS effects, C. difficile.

TMP-SMX harms: hyperkalemia, AKI, SJS/TEN, hemolysis (G6PD), interaction with warfarin.

Cloudy/foul urine, mental status changes alone: not indications to treat.

Methenamine, vaginal estrogen: prevent symptomatic recurrent UTI; not ASB treatment.

Board Question Stem Patterns

— "An 82-year-old nursing home resident is brought in for confusion. UA shows leukocyte esterase positive, nitrites positive. Vitals stable, no dysuria, no flank pain. What is the next best step?"

— Right answer: evaluate alternative causes (med review, hydration, oxygenation, exam) — do not start antibiotics.

— Wrong answers: ceftriaxone, ciprofloxacin, repeat UA.

— "A 68-year-old woman is being evaluated before total knee arthroplasty. Routine UA shows >10⁵ E. coli. She is asymptomatic. Next step?"

— Right answer: proceed with surgery, no treatment.

— Wrong: nitrofurantoin, delay surgery.

— "A 26-year-old G1P0 at 14 weeks' gestation has a urine culture with 10⁵ E. coli; asymptomatic. Next step?"

— Right answer: treat with cephalexin or nitrofurantoin × 5–7 days; test of cure 1–2 weeks later.

— Trap: "no treatment, asymptomatic."

— "A patient with a chronic indwelling Foley has cloudy urine at routine change; afebrile, no symptoms. UA grows mixed flora. Next step?"

— Right answer: no antibiotics; reassess catheter necessity.

— "A man is scheduled for TURP. Preoperative urine culture grows 10⁵ E. coli; asymptomatic. Next step?"

— Right answer: culture-directed antibiotic starting just before procedure, ≤24h postop.

— "A pregnant woman at 16 weeks has GBS in urine at 10⁴ CFU/mL. What next?"

— Right answer: treat the bacteriuria and plan intrapartum penicillin prophylaxis.

— "A renal transplant recipient at 8 months has asymptomatic bacteriuria. Next step?"

— Right answer: no treatment (beyond 1 month, observe).

Step 3 management: Most ASB questions are designed to test restraint. When in doubt, the answer is usually "no antibiotics" — and the second move is to address the inappropriate ordering of the UA in the first place.

The classic ASB trap:

The pre-arthroplasty stem:

The pregnant patient stem:

The catheter stem:

The pre-TURP stem:

The GBS pregnancy stem:

The post-transplant stem:

The "delirium + UA" sepsis stem: look for alternative source — pneumonia, C. diff, intra-abdominal.

One-Line Recap

Treat asymptomatic bacteriuria only in pregnancy and before urologic procedures with mucosal trauma — in every other population (elderly, diabetic, catheterized, SCI, post-transplant >1 month, pre-non-urologic surgery), the right answer is no antibiotics and no repeat culture.

Board pearl: The Step 3 vignette will hand you a positive UA in a frail, elderly, or chronically catheterized patient and dare you to prescribe — the disciplined answer is reassurance, alternative workup for any nonurinary symptoms, education, and a clean discharge summary that prevents the next clinician from doing the wrong thing.

Two-yes rule: Pregnant? Going for TURP/TURBT/ureteroscopy/prostate biopsy? If neither → observe. Memorize this binary and 90% of Step 3 ASB questions become trivial.

Pregnancy-specific: Screen with urine culture at 12–16 weeks (USPSTF Grade A). Treat 4–7 days with cephalexin, nitrofurantoin (not at term), amoxicillin-clavulanate, or single-dose fosfomycin. Obtain test-of-cure culture. GBS bacteriuria at any CFU → treat plus intrapartum penicillin prophylaxis.

Stewardship pearls: Pyuria, cloudy urine, foul odor, and isolated mental status changes are not indications to treat. Inappropriately treating ASB causes C. difficile, resistance, tendinopathy, hyperkalemia, and paradoxically more recurrent symptomatic UTIs in elderly women — and is a tracked quality and Step 3 testing target.

The single most effective CAUTI prevention: remove the catheter. Daily necessity reassessment beats any antibiotic decision. Document "ASB, antibiotics not indicated" to break the cycle of downstream re-treatment.